References

- ¹ Dacie, J V, in *The Haemolytic Anaemias*, part IV. London, Churchill, 1967.
- ² Dausset, J, and Contu, L, *Annual Review of Medicine*, 1967, **18**, 55.
- ³ Beutler, E, *Pharmacological Review*, 1969, **21**, 73.
- ⁴ Chan, T K, Todd, D, and Wong, C C, *British Medical Journal*, 1964, **2**, 102.
- ⁵ Chan, T K, Todd, D, and Wong, C C, *Journal of Laboratory and Clinical Medicine*, 1965, **66**, 937.
- ⁶ Chan, T K, and Todd, D, *British Medical Journal*, 1975, **1**, 131.
- ⁷ Chan, T K, and Todd, D, *American Journal of Human Genetics*, 1972, **24**, 475.
- ⁸ Tso, S C, *British Journal of Haematology*, 1972, **23**, 621.
- ⁹ Chan, T K, and McFadzean, A J S, *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 1974, **68**, 61.
- ¹⁰ Dacie, J V, and Lewis, S M, in *Practical Haematology*, 4th edn. Edinburgh, Churchill Livingstone, 1968.
- ¹¹ Chan, T K, et al, *Journal of Laboratory and Clinical Medicine*, 1971, **77**, 177.
- ¹² Bernini, L, et al, *British Journal of Haematology*, 1964, **10**, 171.
- ¹³ Brewer, G J, et al, *Journal of Laboratory and Clinical Medicine*, 1961, **58**, 217.
- ¹⁴ World Health Organisation, *Treatment of Haemoglobinopathies*, Technical Report Series, No 509, p 61. Geneva, WHO, 1972.
- ¹⁵ McFadzean, A J S, and Choa, G H, *British Medical Journal*, 1953, **2**, 360.
- ¹⁶ Gaetani, et al, *Experientia*, 1970, **26**, 785.
- ¹⁷ Beutler, E, *Blood*, 1970, **36**, 523.
- ¹⁸ Yoshida, A, *Science*, 1973, **179**, 532.
- ¹⁹ Beutler, E, *Blood*, 1959, **14**, 103.
- ²⁰ McCaffrey, R P, et al, *Annals of Internal Medicine*, 1971, **74**, 722.

Reduced respiratory responses to carbon dioxide after propranolol: a central action?

C P MUSTCHIN, H R GRIBBIN, A E TATTERSFIELD, C F GEORGE

British Medical Journal, 1976, **2**, 1229-1231

Summary

In a double-blind study in six subjects propranolol significantly reduced the respiratory sensitivity to carbon dioxide rebreathing. This effect seems to have been due to beta-adrenergic blockade, since it was not seen with D-propranolol. In two subjects increasing doses of propranolol caused progressive reductions in respiratory sensitivity to values below normal and similar to those of patients with ventilatory failure. These changes are probably due to a central action of propranolol.

Introduction

Beta-adrenergic blocking drugs may have deleterious effects in asthmatic patients owing to blockade of endogenous sympathetic drive to bronchial smooth muscle.¹⁻³ In contrast, stimulation of beta-adrenergic receptors relaxes bronchial smooth muscle and also stimulates ventilation.⁴⁻⁷ During recent studies of the effects of propranolol on exercise we noticed a decrease in the ventilatory response in normal subjects. We therefore examined the effect of propranolol on the response to carbon dioxide rebreathing as this correlates well with the ventilatory response to exercise⁸ but is easier to measure.

We measured both the ventilatory and the maximum rate of inspiratory pressure development ($dP/dt_{\max}$) responses to hypercapnia.⁹ The latter measurement is a function of the initial contraction of the respiratory muscles and occurs before any significant flow of gas begins. It may, therefore, be regarded as a reflection of output from the "respiratory centre" and may be a more accurate index of the drive to breathe than measurements of ventilation alone. If the lungs are mechanically abnormal simple measurements of ventilation may underestimate the drive

to breathe because of inefficient conversion of respiratory work into ventilation. Writers have disagreed about the effects of propranolol on airway resistance in normal subjects,¹⁰⁻¹⁴ but if airway resistance were to rise ventilation might fall as a consequence and give a false impression of respiratory responsiveness to CO_2 stimulation.

To separate the beta-adrenergic blocking properties of propranolol from its other actions we examined the effects of both the commercially available racemic mixture (DL-propranolol) and the dextrorotatory isomer (D-propranolol). The latter has only 1/60th of the beta-adrenergic blocking function of the racemic mixture¹⁵ but has similar membrane-stabilising activity.

Patients and methods

Six healthy volunteers aged 22-35 took part. None were receiving regular medication nor was there any previous history of asthma.

Carbon dioxide rebreathing was performed according to the method of Read¹⁶ as modified by Matthews and Howell.⁹ Progressive hypercapnia was produced by rebreathing mixtures of 5% CO_2 in oxygen. Ventilation was determined by displacing air from a bag in bottle arrangement. A manometer line placed at the mouth was used to detect pressure changes and the signal was electronically differentiated to give $dP/dt_{\max}$ for each breath. End tidal CO_2 levels were recorded throughout using a Godart Capnograph and were allowed to increase up to values of 9-10%.

Regressions of ventilatory and $dP/dt_{\max}$ responses on end tidal PCO_2 were calculated by the method of least squares. All were highly linear at high CO_2 levels ($r > 0.9$). The slope of the lines was taken as a measure of sensitivity to CO_2 . The slopes and x-intercept values of the extrapolated line were compared by Wilcoxon's signed-ranks test for paired data.

Spirometry was performed before and after drug administration.

FIRST STUDY

The effects of DL-propranolol (80 mg) and an identical placebo were compared in a double-blind study. The CO_2 responses were determined on separate days, two hours after oral administration of the tablets in the fasting state. On another occasion two of the subjects had repeated doses of propranolol (40, 40, and 80 mg) every two hours to establish a dose-response relation. Venous blood samples were taken after each series of respiratory response measurements and plasma concentrations were estimated fluorometrically using the method of Shand et al.¹⁷

Southampton University Hospitals, Southampton

C P MUSTCHIN, MB, MRCP, research fellow

H R GRIBBIN, MB, MRCP, research fellow

A E TATTERSFIELD, MD, MRCP, senior lecturer in medicine

C F GEORGE, MD, MRCP, professor of clinical pharmacology

SECOND STUDY

The effect of D-propranolol (100 mg) was investigated in an open study. Responses were measured before and two hours after drug administration.

Results

DL-Propranolol significantly reduced the ventilatory response to carbon dioxide (see figure and table I): the mean reduction in the slope of the regression was 46.6% ($P < 0.05$). The intercept values were not significantly changed. Subjects who showed the greatest initial response to inhaled CO_2 showed the greatest reduction after propranolol ($r = 0.84$; $P < 0.01$). Similar statistically significant changes

Ventilatory response to CO_2 before (open symbols) and after (closed symbols) propranolol in subject No 5.

TABLE I—Effects of racemic (DL) propranolol on CO_2 response (first study)

Subject No	Control	DL-Propranolol	Control	DL-Propranolol
<i>Ventilation</i>				
	Slope of response (l/min/kPa)		x-Intercept value (kPa)	
1	31.75	24.13	6.29	6.42
2	9.68	4.78	0.30	4.15
3	18.80	11.38	6.45	6.13
4	42.63	14.44	5.95	5.10
5	26.94	9.05	6.08	4.81
6	27.40	20.09	5.92	5.09
Mean	26.20	13.98	5.17	5.28
<i>dP/dt_{max}</i>				
	Slope of response (kPa/s/kPa)		x-Intercept value (kPa)	
1	2.94	1.95	6.68	6.43
2	0.78	0.45	1.73	1.79
3	2.33	1.16	6.77	6.13
4	4.40	0.95	5.73	3.86
5	3.16	0.74	6.21	4.93
6	4.57	1.98	6.22	0.36
Mean	3.03	1.21	3.31	3.2

Conversion: SI to traditional units—1 kPa $\approx$ 7.5 mm Hg.

TABLE II—Dose-response study in two subjects

	Plasma propranolol concentration (ng/ml)	Slope of ventilatory response (l/min/kPa)	Slope of dP/dt _{max} response (kPa/s/kPa)
Subject No 2			
Control value	0	11.21	0.66
After 1st dose	29	8.95	0.46
After 2nd dose	34	6.10	0.60
After 3rd dose	104	3.47	0.23
Subject No 5			
Control value	0	24.50	3.59
After 1st dose	64	18.98	3.00
After 2nd dose	112	19.05	2.47
After 3rd dose	232	8.55	0.84

were noted in the dP/dt_{max} response ($P < 0.05$). There was also a dose-related reduction in carbon dioxide sensitivity (table II).

There were no significant changes in the forced expiratory volume in 1 second (FEV₁) after propranolol. D-Propranolol had no significant effect on either the ventilatory or dP/dt_{max} response to CO_2 (table III).

TABLE III—Effects of D-propranolol on CO_2 response (second study)

Subject No	Control	DL-Propranolol	Control	DL-Propranolol
<i>Ventilation</i>				
	Slope of response (l/min/kPa)		x-Intercept value (kPa)	
1	32.81	31.17	6.13	6.27
2	11.27	13.52	4.57	5.23
3	19.38	22.50	6.08	6.27
4	43.40	46.20	6.15	6.04
5	25.22	17.98	6.56	5.48
6	31.74	38.73	5.49	5.80
Mean	27.30	28.35	5.83	5.85
<i>dP/dt_{max}</i>				
	Slope of response (kPa/s/kPa)		x-Intercept value (kPa)	
1	3.04	3.40	6.18	6.22
2	0.59	0.77	4.66	5.13
3	1.64	2.31	6.26	6.28
4	3.95	5.03	6.12	6.01
5	3.66	3.10	6.39	6.16
6	4.56	4.74	5.77	6.05
Mean	2.91	3.23	5.89	5.98

Discussion

These studies show that propranolol significantly reduces CO_2 responsiveness in normal volunteers. In the dose-response study the reduced CO_2 responsiveness eventually resembled that seen in bronchitic patients with CO_2 insensitivity and retention.¹⁸ D-Propranolol had no effect, so the observed effects must have been due to beta-blockade.

There are several possible explanations for the observed changes in responsiveness. Significant changes in lung mechanics were unlikely to have occurred as there was no disparity between dP/dt_{max} and ventilation; also the FEV₁ was unchanged. Although the CO_2 feedback control circuit is partly modulated by peripheral chemoreceptors that are under sympathetic control,¹⁹ the medullary chemoreceptor is probably of major importance.^{18, 20} Our experiments were performed under hyperoxic conditions, which would reduce the peripheral component of the CO_2 response,²¹ and in view of the magnitude of changes it is likely that propranolol was acting centrally.

Propranolol has been identified in human brain tissue²² and may produce central nervous system side effects such as nightmares and hallucinations. A central action was proposed in a study of essential tremor.²³ Central action has also been postulated on the basis of hypotension after the intracerebroventricular injection of the drug in hypertensive rabbits,²⁴ but so far there has been little convincing evidence for a pharmacological action on the vital centres in man.

Our findings suggest that propranolol has a central action after oral doses of only 80 mg. This property may not be common to all beta-blocking drugs since their ability to enter the central nervous system varies greatly; current studies are investigating this further.

Although some workers^{25, 26} have claimed that propranolol is safe in patients with chronic bronchitis our results suggest that caution should be exercised in treating such patients, who may be at risk from respiratory depression, particularly during sleep.

We thank Professor J B L Howell for advice, Dr M Castleden for performing the plasma assays, and Miss L Henry for technical help. CPM is supported by a Proffit Scholarship of the Royal College of Physicians. HRG is in receipt of a Burroughs Wellcome grant. ICI kindly supplied the D-propranolol.

References

- ¹ Langer, I, *Journal of Physiology*, 1967, **190**, 41P.
- ² Beumer, H M, *Lancet*, 1967, **2**, 993.
- ³ McNeil, R S, *Lancet*, 1964, **2**, 1101.
- ⁴ Whelan, R F, and Young, I M, *British Journal of Pharmacology*, 1953, **8**, 98.
- ⁵ Young, I M, *Journal of Physiology*, 1957, **137**, 374.
- ⁶ Lamberts, C J, in *Handbook of Physiology*, section 3, vol 1, ed W O Fenn and H Rahn, p 551. Washington, American Physiological Society, 1964.
- ⁷ Leitch, A G, *et al*, *British Medical Journal*, 1976, **1**, 365.
- ⁸ Rebuck, A S, Jones, N L, and Campbell, E J M, *Clinical Science*, 1972, **43**, 861.
- ⁹ Matthews, A W, and Howell, J B L, *Clinical Science and Molecular Medicine*, 1975, **49**, 57.
- ¹⁰ McNeil, R S, and Ingram, C G, *American Journal of Cardiology*, 1966, **18**, 473.
- ¹¹ Macdonald, A G, Ingram, C G, and McNeill, R S, *British Journal of Anaesthesia*, 1967, **39**, 919.
- ¹² Richardson, P S, and Sterling, G M, *British Medical Journal*, 1969, **3**, 143.
- ¹³ Tattersfield, A E, Leaver, D G, and Pride, N B, *Journal of Applied Physiology*, 1973, **35**, 613.
- ¹⁴ Gayard, P, *et al*, *Thorax*, 1975, **30**, 657.
- ¹⁵ Barrett, A M, and Cullum, V A, *British Journal of Pharmacology*, 1968, **34**, 43.
- ¹⁶ Read, D J C, *Australasian Annals of Medicine*, 1967, **16**, 20.
- ¹⁷ Shand, D G, Nickolls, E M, and Oates, J A, *Clinical Pharmacology and Therapeutics*, 1970, **2**, 112.
- ¹⁸ Matthews, A W, and Howell, J B L, *Clinical Science and Molecular Medicine*, 1976, **50**, 199.
- ¹⁹ Purves, M J, and Biscoe, T J, in *Arterial Chemoreceptors*, ed P W Torrance. Oxford, Blackwell, 1968.
- ²⁰ Read, D J C, and Leigh, J, *Journal of Applied Physiology*, 1967, **23**, 53.
- ²¹ Lefrançois, R, *et al*, *Respiration Physiology*, 1972, **14**, 296.
- ²² Myers, M G, *et al*, *Journal of Pharmacology and Experimental Therapeutics*, 1975, **192**, 327.
- ²³ Young, R, Growdon, J H, and Shahani, B T, *New England Journal of Medicine*, 1975, **293**, 950.
- ²⁴ Bakke, O M, *et al*, *British Journal of Pharmacology*, 1974, **51**, 148P.
- ²⁵ Stone, D J, Kelts, H, and Samorin, T, *American Review of Respiratory Disease*, 1971, **103**, 503.
- ²⁶ Nordstrom, L A, Macdonald, F, and Gobel, F L, *Chest*, 1975, **67**, 287.

SHORT REPORTS

Persistent intestinal protein loss after measles

Measles is one of the commonest precipitating factors in kwashiorkor.¹ There is appreciable intestinal protein loss during acute measles infection in underweight children with diarrhoea,^{2,3} and I have investigated the possibility that if this persists it might cause kwashiorkor.

Patients, methods, and results

Six children with persistent diarrhoea after measles were studied. The history of measles was confirmed either by documentation during the acute illness or by post-measles skin staining on examination. None had diarrhoea before the onset of measles. Their ages ranged from 20 months to 9 years (mean age 38 months). All weighed less than 80% of the Harvard standard growth curve (mean value $59 \pm \text{SD } 10\%$). Their mean serum albumin level was 23 ± 4 g/l. Three of the children had developed oedema since the acute illness. Stool culture grew no important pathogens. One child had ova of *Schistosoma mansoni* in the stool. Controls were five children who had recovered from measles but were being reinvestigated after intestinal protein loss had been found during acute measles, as described previously.² Their mean age was 30 ± 13 months, and their mean weight $81 \pm 15\%$ of the Harvard standard growth curve.

⁵⁹Fe-labelled iron dextran (⁵⁹FE) was used to measure intestinal protein loss. A dose of $0.1 \mu\text{Ci/kg}$ was injected intravenously, and all stools over the next three days were collected. Plasma was sampled daily. The faecal clearance of ⁵⁹FE thus calculated correlated closely with plasma protein loss into the gut.⁴ With the assumption that albumin is cleared similarly to ⁵⁹FE,⁴ the absolute albumin loss was estimated from the faecal ⁵⁹FE clearance and calculated total intravascular albumin pool. The mean faecal clearance in the patients with post-measles diarrhoea was $6.5 \pm 4.2\%$ of the plasma volume daily. This was significantly higher than in the controls, whose clearance was $2.0 \pm 0.9\%$ of the plasma volume daily ($t = 2.6$; $P < 0.05$). Those with oedema had a greater clearance than those without oedema (see figure). The mean absolute albumin loss was significantly ($P < 0.05$) greater in the patients with post-measles diarrhoea (0.9 ± 0.7 g/day) than in the controls (0.4 ± 0.3 g/day).

Discussion

The patients with post-measles diarrhoea continued to lose protein in the stool two to four weeks after measles, having a similar ⁵⁹FE clearance to that found in acute measles² and a significantly higher clearance than children who had recovered from measles.

Kwashiorkor developed in the three patients with the highest protein losses. The mean absolute albumin loss in all the patients with post-measles diarrhoea was almost 1 g daily—an important loss, since their mean total intravascular albumin pool was only 13 ± 4 g. The mean loss of 0.4 g albumin daily in the controls was from a mean total intravascular albumin pool of 24 ± 7 g. Shukry *et al*⁵ found that children with kwashiorkor lost little protein in the stool in the absence

Clearance of ⁵⁹FE-labelled iron dextran in six patients with post-measles diarrhoea and five controls ($t = 2.6$; $P < 0.05$).

of diarrhoea, and our unpublished results confirm this. Thus the protein loss in the patients with post-measles diarrhoea was related to the diarrhoea and not to the poor state of nutrition.

We do not know whether measles virus has any specific role in the syndrome of post-measles diarrhoea. Superinfection by bacteria or fungi in the large bowel or small bowel is a possible explanation, since secondary infections after measles are common in other tissues. Possibly underweight children with diarrhoea from any cause may lose similar amounts of protein to the children in this study.

I thank Dr Norman Veall for the ⁵⁹FE-labelled iron dextran, and Dr H Whittle and Dr B M Greenwood for their help.

¹ Ogbeide, M I, *West African Medical Journal*, 1971, **20**, 313.

² Dossetor, J F B, and Whittle, H C, *British Medical Journal*, 1975, **2**, 592.

³ Axton, J H M, *British Medical Journal*, 1975, **3**, 79.

⁴ Jarnum, S, *et al*, *Gastroenterology*, 1968, **55**, 229.

⁵ Shukry, A S, *et al*, *Journal of Tropical Medicine and Hygiene*, 1965, **68**, 269.

Department of Paediatrics, Ahmadu Bello University, Zaria, Nigeria

J F B DOSSETOR, DCH, MRCP, lecturer in paediatrics